Cold Chain Technologies (CCT), a global leader in temperature-controlled packaging, has played a pivotal role in demonstrating the viability of ocean freight for high value temperature sensitive pharmaceutical shipments, through a landmark project with logistics leaders Kuehne + Nagel and Teva Pharmaceuticals.
The project, which validated the transportation of temperature-sensitive pharmaceuticals on one of the world’s most demanding sea routes – from Germany to Australia – has shown that sea freight can offer a viable, cost-effective and more sustainable* alternative to air cargo.
Despite facing a series of extreme logistical setbacks, the shipment arrived in perfect condition, thanks in part to Enshield, a high-performance, reusable PCM thermal blanket from Cold Chain Technologies.
Qualifying the route meant meeting the challenge of maintaining quality and compliance over the longer distances, and durations, associated with sea travel. Given the rigid quality and regulatory requirements, all partners agreed that the approach had to be approved on a live test, rather than digital simulation.
